A Phase 1b Open Label Clinical Trial to Evaluate HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2019
At a glance
- Drugs HIV gp120 vaccine (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Pharmacodynamics
- 14 Jan 2019 Status changed from not yet recruiting to recruiting.
- 10 Dec 2018 Planned End Date changed from 15 Apr 2020 to 15 Sep 2020.
- 10 Dec 2018 Planned primary completion date changed from 15 Apr 2020 to 15 Sep 2020.